A similar observation in vivo of PD-L1 expression on CD45- tumor cells revealed that Mit-A sensitizes the tumor cells by increasing its expression, which was decreased when, combined with αPD-L1 therapy (Figure 5E). Here, PTPRC is linked to neoplasm.